Economic Pressures Increasingly Concern Private-Pay Oncology
Once shy about discussing expenses with patients, oncologists increasingly are opening up about the nitty gritty of drug costs during office visits
You may also be interested in...
Selection of key research notably includes no real advances in commercial drug development.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.